On October 22, 2024, Ocuphire Pharma, Inc. announced the acquisition of privately held Opus Genetics, Inc. This transformative all-stock transaction led to the combined entity rebranding as Opus Genetics, Inc., signaling a decisive strategic pivot.
The acquisition positions the company as a clinical-stage leader focused on developing gene therapies for inherited retinal diseases (IRDs). This move shifts the company's core strategy towards a high-risk, high-reward segment of the biopharmaceutical market.
The newly combined company aims to leverage a promising portfolio of gene therapy assets, including OPGx-LCA5 and OPGx-BEST1, which now form the cornerstone of its long-term growth strategy in addressing unmet medical needs in IRDs.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.